FIRTECAN PEGOL - PharmaKB

FIRTECAN PEGOL

Firtecan pegol is a small molecule pharmaceutical. It is currently being investigated in clinical studies.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

No data

Clinical

Clinical Trials

22 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

No data

Indications Phases 3

No data

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Neoplasms	D009369	—	C80	3	1	—	—	—	3
Colorectal neoplasms	D015179	—	—	—	1	—	—	—	1
Breast neoplasms	D001943	EFO_0003869	C50	—	1	—	—	—	1

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Lymphoma	D008223	—	C85.9	2	—	—	—	—	2

Indications Without Phase

No data

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	FIRTECAN PEGOL
INN	firtecan pegol
Description	Firtecan pegol is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Classification	Small molecule
Drug class	PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer; antineoplastics (camptothecin derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	—